SCHEMBL6229258

SCHEMBL6229258

NS(=O)(=O)c1ccccc1S(=O)(=O)c1ccc(Cn2c(-c3ccccc3)nc(Cl)c2C=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.39
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PTGS2 P35354 1/20 0.37
CA2 P00918 5/20 0.36
CA1 P00915 3/20 0.36
CA12 O43570 2/20 0.36
CA9 Q16790 2/20 0.36
CA4 P22748 3/20 0.36
CA7 P43166 3/20 0.36
KDR P35968 1/20 0.36
LMNA P02545 2/20 0.36
RECQL P46063 1/20 0.36
RAB9A P51151 1/20 0.36
PDE6D O43924 1/20 0.35
ALDH2 P05091 1/20 0.35
ALDH3A1 P30838 1/20 0.35
DHFR P00374 1/20 0.35
GHSR Q92847 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7609835 0.86 GP6 (0.42) ALDH1A1SMN1; SMN2AGTR2
SCHEMBL7262643 0.84 PTGDR2 (0.36) PTGDR2ALDH1A1SMN1; SMN2LMNARECQL
SCHEMBL6231352 0.83 PTGDR2 (0.36) PTGDR2ALDH1A1SMN1; SMN2LMNADHFR
SCHEMBL6231353 0.83 PTGDR2 (0.36) PTGDR2ALDH1A1SMN1; SMN2LMNADHFR
SCHEMBL11160756 0.80 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2LMNARECQLRAB9A
SCHEMBL11097622 0.79 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNARECQLRAB9A
SCHEMBL7648058 0.78 TP53 (0.42) SMN1; SMN2TP53
SCHEMBL6229212 0.78 CA1 (0.38) ALDH1A1SMN1; SMN2CA2CA1CA12
SCHEMBL6202033 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2LMNARECQLRAB9A
SCHEMBL5174986 0.76 AGTR1 (0.39) PTGDR2ALDH1A1SMN1; SMN2PTGS2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1076651-B1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT AVENTIS PHARMA GMBH (DE) 2005-04-20 EP disclosed
US-6573288-B1 Compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-06-03 US disclosed
EP-1076651-A1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT Aventis Pharma Deutschland GmbH (DE) 2001-02-21 EP disclosed
WO-1999057102-A1 SUBSTITUTED SULPHONYL CYANAMIDES, METHOD FOR PRODUCING SAME AND THEIR USE AS MEDICAMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 1999-11-11 WO disclosed